71 papers found
Refreshing results…
12885 2016 2105 Moesm2 Esm
Transgelin increases metastatic potential of colorectal cancer cells in vivo and alters expression of genes involved in cell motility
Additional file 2: Table S2. of Transgelin increases metastatic potential of colorectal cancer cells in vivo and alters expression of genes involved in cell motility
Additional file 1: Table S1. of Transgelin increases metastatic potential of colorectal cancer cells in vivo and alters expression of genes involved in cell motility
A model of BCR-FGFR1 driven human AML in immunocompromised mice
FGFR1OP2-FGFR1 induced myeloid leukemia and T-cell lymphoma in a mouse model
Abstract 817: Sepantronium is a DNA damaging agent that potentiates PLK1 inhibitor volasertib
Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib
HOXC9 directly regulates distinct sets of genes to coordinate diverse cellular processes during neuronal differentiation
Dysregulated signaling pathways in the development of CNTRL-FGFR1–induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models
Abstract B11: YM155 synergizes with Plk1 inhibitor volasertib in killing of non-small cell lung cancer
PGPIPN, a Therapeutic Hexapeptide, Suppressed Human Ovarian Cancer Growth by Targeting BCL2
Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities
Supplementary Material
Figure S1
Table S1
Acute Progression of BCR-FGFR1 Induced Murine B-Lympho/Myeloproliferative Disorder Suggests Involvement of Lineages at the Pro-B Cell Stage
Figure S2
Additional 1: Table S1.
NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors
Missing publications? Read more about our data sources.